Antirobe Capsules contain Clindamycin and are used for:

  • For the treatment of infected wounds and abscesses, and infected mouth cavity and dental infections, caused by or associated with Staphylococcus spp., Streptococcus spp. (except Streptococcus faecalis), Bacteroides spp., Fusobacterium necrophorum and Clostridium perfringens. To help provide antimicrobial cover during dental procedures.
  • For the treatment of superficial pyoderma associated with Staphylococcus intermedius.
  • For the treatment of osteomyelitis, caused by Staphylococcus aureus.
Cats (25mg only): 
  • For the treatment of infected wounds and abscesses and infected mouth cavity and dental infections, caused by bacteria sensitive to clindamycin. To help provide antimicrobial cover during dental procedures.
  • Before Antirobe therapy is initiated, the involved pathogens should be identified and sensitivity to clindamycin established.
  • Clindamycin has been shown to have in vitro activity against isolates of the following organisms:
  • Aerobic Gram-positive cocci, including: Staphylococcus intermedius and Staphylococcus aureus (penicillinase and non-penicillinase producing strains), Staphylococcus epidermidis, Streptococcus spp. (except Streptococcus faecalis), Pneumococcus spp.
  • Anaerobic Gram-negative bacilli, including: Bacteroides spp., Fusobacterium spp.
  • Anaerobic Gram-positive non-spore-forming bacilli, including: Propionibacterium spp., Eubacterium spp., Actinomyces spp.
  • Anaerobic and microaerophilic Gram-positive cocci, including: Peptococcus spp., Peptostreptococcus spp., microaerophilic streptococci.
  • Clostridia: Most Cl.perfringens are susceptible; other species such as Cl. sporogenes and Cl. tertium frequently are resistant to clindamycin.
  • Mycoplasma species: Most mycoplasma species are susceptible to clindamycin.
  • The use of Antirobe Capsules is contra-indicated in animals which are hypersensitive to preparations containing clindamycin or lincomycin.
  • Do not administer to rabbits, hamsters, guinea pigs, chinchillas, horses or ruminants because ingestion of clindamycin by these species may result in severe gastro-intestinal disturbance.
  • Clindamycin and erythromycin show parallel resistance. Partial cross-resistance has been demonstrated between clindamycin, erythromycin and other macrolide antibiotics.
  • Clindamycin hydrochloride has been shown to have neuromuscular blocking properties that may enhance the action of other neuromuscular blocking agents. Antirobe Capsules should be used with caution in animals receiving such agents.
  • Clindamycin should not be used concomitantly with chloramphenicol or macrolides as they antagonise each other at their site of action at the 50S ribosomal sub-unit.
  • Vomiting and diarrhoea have occasionally been observed.
  • Antirobe sometimes causes the overgrowth of non-sensitive organisms such as resistant clostridia and yeasts. In cases of superinfection, appropriate measures must be taken according to the clinical situation.
  • During prolonged therapy of one month or greater, periodic liver and kidney function tests and blood counts should be performed.
  • Animals with severe renal and/or very severe hepatic disturbances accompanied by severe metabolic aberrations should be dosed with caution and should be monitored by serum examination during high-dose clindamycin therapy.
  • While high dose studies in rats suggest that clindamycin is not a teratogen and does not significantly affect the breeding performance of males and females, safety in gestating bitches/queens or breeding male dogs/cats has not been established.
  • Wash hands after handling the capsules.

For more information, please use the following link: https://www.noahcompendium.co.uk/?id=-456449

Antirobe Capsules